

## June 2015 Appendix 4C

### **Melbourne, Australia, 30 July 2015**

Prescient Therapeutics Limited (“**Prescient**” or “**the Company**”) provides the following Appendix 4C in relation to the quarter ended 30 June 2015.

During the quarter, Prescient secured agreement from the United States Food and Drug Administration (FDA) to transfer the sponsorship to Prescient of the Investigational New Drug (IND) – PTX-200, the company’s lead product.

Prescient also announced highly encouraging data from a pre-clinical trial of its novel compound PTX-100 in multiple myeloma at a prestigious US oncology conference. Moffitt Cancer Center scientists examined the effect of Prescient’s small molecule compound PTX-100, a GGT-1 inhibitor that targets one of the RAS signaling pathways, in a mouse model highly relevant to multiple myeloma. They found the compound significantly decreased the percentage of multiple myeloma tumors within the bone and also offered a substantial improvement on mouse median survival times.

During the quarter, Prescient appointed an internationally regarded pharmaceutical executive as Chief Medical Officer, Dr Terrence Chew, who will oversee clinical development and regulatory strategy for Prescient’s two novel oncology candidates now in mid-stage clinical trials at leading US cancer centres.

Also during the quarter, Prescient announced the appointment of Professor Said M. Sebti, Ph.D., the Chair of Drug Discovery at the 3<sup>rd</sup> largest cancer centre in the US, Moffitt Cancer Center. Professor Said M. Sebti has joined Prescient as Chief Scientific Officer.

On 10 June 2015 the Company was notified by the US Food and Drug Administration (FDA) that it has reactivated the Investigational New Drug (IND) for its novel drug candidate PTX-100 (formerly known as GGTI-2418) in a Phase Ib trial for the treatment of metastatic breast cancer. As part of this reactivation notification from the FDA, and in accordance with the terms of the acquisition of the drug from Pathway in mid-2014, the Company issued 4,500,000 fully paid ordinary shares to the previous shareholders of Pathway Oncology Pty Ltd in line with its obligations under the Milestone 1 consideration.

On 29 June 2015 the Company announced that it has notified the US Food and Drug Administration (FDA) of the transfer of the Investigational New Drug (IND) for its novel drug candidate PTX-200 (formerly known as TCN-P) in Phase 1b/2 trial for the treatment of metastatic ovarian cancer. The IND was previously held by an Investigator at the Moffitt Cancer Center. This follows the acquisition of the drug from AKTivate Therapeutics in late 2014.

Two clinical trials are currently underway for PTX-200 in breast cancer and ovarian cancer remain funded by US government grants.

### **Cash at 30 June 2015**

Cash at the end of the quarter, as detailed in the attached Appendix 4C, was approximately \$1.043 million. The reduced expenditure during the last quarter compared to previous quarters reflects prior one-off costs associated with the acquisition of AKTivate Pty Ltd and clinical program initiation as well as the Company's efforts to rationalise ongoing cash expenditure.

### **About Prescient Therapeutics**

Prescient Therapeutics is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study of PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. The second is also a Phase 1b/2 trial in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's Lee Moffitt Cancer Center. In addition, Prescient is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia in 2015.

Prescient's second novel drug candidate, PTX-100, is a first in class compound with the ability to block important cancer-causing proteins such as Ral and Rho, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors. Prescient expects to commence Phase 1b/2 clinical trials in breast cancer and multiple myeloma in 2015. At the same time, Prescient plans to develop its novel p27 cancer biomarker as a companion diagnostic that will potentially identify those patients that are most likely to respond to PTX-100 therapy.

Prescient has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.

### **Contact:**

Dr Robert Crombie (Managing Director)

Ms Melanie Leydin (Company Secretary)

Ph: +61 (0) 3 9692 7222

# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005, 17/12/2010

Name of entity

Prescient Therapeutics Limited (Formerly Virax Holdings Limited)

ABN

56 006 569 106

Quarter ended ("current quarter")

30 June 2015

### Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (12 months) \$A'000
1.1 Receipts from customers	-	-
1.2 Payments for:		
(a) staff costs	(151)	(351)
(b) advertising and marketing	(16)	(134)
(c) research and development	(100)	(814)
(d) leased assets	-	-
(e) other working capital	(184)	(1,140)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	2	39
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other items		
(a) Net GST (paid to)/recovered from ATO	-	-
(b) R & D tax rebate received	-	-
(c) Government grant received	-	-
(d) R&D contract contributions received	-	-
<b>Net operating cash flows</b>	<b>(449)</b>	<b>(2,400)</b>

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

	Current quarter \$A'000	Year to date (12 months) \$A'000
1.8 Net operating cash flows (carried forward)	(449)	(2,400)
<b>Cash flows related to investing activities</b>		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	(364)
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:	-	-
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
<b>Net investing cash flows</b>	-	(364)
<b>1.14 Total operating and investing cash flows</b>	-	(2,764)
<b>Cash flows related to financing activities</b>		
1.15 Proceeds from issues of shares, options, etc.	-	-
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Capital raising costs	-	-
<b>Net financing cash flows</b>	-	-
<b>Net increase (decrease) in cash held</b>	(449)	(2,764)
1.21 Cash at beginning of quarter/year to date	1,477	3,786
Exchange rate adjustments to item 1.20	15	21
1.23 <b>Cash at end of quarter</b>	1,043	1,043

+ See chapter 19 for defined terms.

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	151
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Directors' fees and Executive Directors' salaries paid during the June 2015 quarter.
--

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

On 23 June 2015 the Company issued 4,500,000 fully paid ordinary shares following satisfaction of the Milestone 1 criteria in relation to the acquisition of Pathway Oncology Pty Ltd as approved by shareholders on 9 May 2014.
--

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

-
---

**Financing facilities available**

*Add notes as necessary for an understanding of the position.*

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

---

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	1,043	1,477
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
<b>Total: cash at end of quarter</b> (item 1.23)	1,043	1,477

**Acquisitions and disposals of business entities**

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	-	-
5.2 Place of incorporation or registration	-	-
5.3 Consideration for acquisition or disposal	-	-
5.4 Total net assets	-	-
5.5 Nature of business	-	-

**Compliance statement**

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:   
 \_\_\_\_\_  
 (Company Secretary)

Date: 30 July 2015

Print name: Melanie Leydin

---

+ See chapter 19 for defined terms.

## Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirement requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

---

+ See chapter 19 for defined terms.